Neurotechnology - Bladder Dysfunction

Created with AI

WEARABLES FOR THE BLADDER

WeB STUDIES

Funded by the National MS Society

  1. Phase I - REMOTE BLADDER MONITORING PILOT - IN MULTIPLE SCLEROSIS
  2. Phase II - PELVIC FLOOR PT AND WEARABLES INTERVENTION PILOT - IN MULTIPLE SCLEROSIS

FUNDED BY a RAP GRANT

    3. Wearables in the Clinic - POSTPARTUM WOMEN AND MEN POST-PROSTATECTOMY

 

 

News

Stakeholder Engagement

Presented at the 2023 Consortium of MS Centers, Aurora DO

 

Monitoring Phase I                              Presented at 2024 American Academy of Neurology Conference & the 2024 Consortium of MS Centers

 

 

Wearables for the Bladder: 

remote monitoring using commercially available bladder wearables

We are using a commercially available non-invasive wearable bladder untrasound at home and comparing it with in-clinic gold-standard testing. 

For more information please email Valerie ([email protected]) 

Wearables for the Bladder:

an In-home Treatment Feasibility Pilot Study (WeB)

We are piloting the use of commerically available bladder wearables (for example: a non-invasive bladder ultrasound that connects to a smart phone for bladder fullness, and a active kegel exercise device) together with pelvic floor PT to improve urinary incontinence and quality of life outcomes in people with multiple sclerosis (MS). 

Learn more

 
For more information, contact Valerie: [email protected]

Exploring Clinical Utility of Wearables for the Bladder in Pelvic Health Physical Therapy Clinics 

PI: VJ Block

Co-Is: J. Kinder, L. McIntyre (Né: Wylie), J. LaBrec

- with  R.Souza 

Pelvic floor physical therapy (PFPT) is a validated intervention for bladder dysfunction (BD) and pelvic floor disorders (PFD) in postpartum women and men, yet objective, remote outcome measures are lacking. Our study evaluates the potential of wearables for the bladder (WeB), including a wearable ultrasound device and an intravaginal exerciser, to provide accurate, actionable data for BD and PFD management. Initial findings in multiple sclerosis patients indicate strong potential, but broader effectiveness across diverse demographics remains unconfirmed.

Here, we aim to validate WeB's accuracy and utility in these groups, assess its responsiveness to therapy changes, and evaluate user experience. This research intends to bridge care gaps, offering personalized, continuous treatment strategies and enhancing care inclusivity and effectiveness for BD and PFD.

RECRUITMENT IS SET TO START SUMMER 2024

 

Funded by: RAP Pilot for Early Career Investigators Grant (“NIH Natl Ctr Advancing Translational Sci")